{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:27:16Z","timestamp":1788550036870,"version":"build-2803163510"},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,1,25]]},"DOI":"10.18632\/oncotarget.28182","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T14:00:15Z","timestamp":1643119215000},"page":"214-223","source":"Crossref","is-referenced-by-count":16,"title":["Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECCY Trial"],"prefix":"10.18632","volume":"13","author":[{"given":"Mauro Rog\u00e9rio de Barros","family":"Wanderley Jr.","sequence":"first","affiliation":[{"name":"Heart Failure Department, Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica Samuel","family":"\u00c1vila","sequence":"additional","affiliation":[{"name":"Heart Failure Department, Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Morita","family":"Fernandes-Silva","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidade Federal do Paran\u00e1, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima das Dores","family":"Cruz","sequence":"additional","affiliation":[{"name":"Heart Failure Department, Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Michelly Gon\u00e7alves","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"Heart Failure Department, Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vagner Oliveira Carvalho","family":"Rigaud","sequence":"additional","affiliation":[{"name":"Heart Failure Department, Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludhmila Abrah\u00e3o","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo-Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Kalil","family":"Filho","sequence":"additional","affiliation":[{"name":"Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo-Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed\u00e9cio","family":"Cunha-Neto","sequence":"additional","affiliation":[{"name":"Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edimar Alcides","family":"Bocchi","sequence":"additional","affiliation":[{"name":"Heart Failure Department, Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Moreira","family":"Ayub-Ferreira","sequence":"additional","affiliation":[{"name":"Heart Failure Department, Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"7","author":"Jemal","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fphar.2018.01262","article-title":"Updates in Anthracycline-Mediated Cardiotoxicity","volume":"9","author":"D\u00e9saubry","year":"2018","journal-title":"Front Pharmacol"},{"key":"3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"10","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"1","author":"Piepoli","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"5","author":"Cipolla","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"6","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"10","author":"Cipolla","year":"2004","journal-title":"Circulation"},{"key":"7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"3","author":"Steine","year":"2016","journal-title":"Eur Heart J"},{"key":"8","doi-asserted-by":"publisher","first-page":"e006513","DOI":"10.1161\/JAHA.117.006513","article-title":"Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study","volume":"6","author":"Omland","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"9","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial","volume":"7","author":"de Paula Costa","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/eurjhf\/hft106","article-title":"Biomarkers of heart failure with normal ejection fraction: a systematic review","volume":"1","author":"Kardys","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","article-title":"Role of Endothelium in Doxorubicin-Induced Cardiomyopathy","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1161\/01.CIR.0000090690.67322.51","article-title":"Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes","volume":"10","author":"Hamm","year":"2003","journal-title":"Circulation"},{"key":"13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1373\/clinchem.2009.142257","article-title":"Use of myeloperoxidase for risk stratification in acute heart failure","volume":"5","author":"Mueller","year":"2010","journal-title":"Clin Chem"},{"key":"14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clinbiochem.2014.10.013","article-title":"Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity","volume":"4","author":"Park","year":"2015","journal-title":"Clin Biochem"},{"key":"15","doi-asserted-by":"publisher","first-page":"2958219","DOI":"10.1155\/2018\/2958219","article-title":"Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy","volume":"201","author":"Pankuweit","year":"2018","journal-title":"Dis Markers"},{"key":"16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00280-015-2874-9","article-title":"Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients","volume":"7","author":"de Geus-Oei","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1373\/clinchem.2016.257550","article-title":"Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study","volume":"6","author":"Rothenbacher","year":"2016","journal-title":"Clin Chem"},{"key":"18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"9","author":"van Veldhuisen","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"4","author":"Pinto","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"6","author":"Picard","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"21","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","article-title":"Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab","volume":"6","author":"Banchs","year":"2015","journal-title":"Clin Chem"},{"key":"22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/01.ATV.0000163262.83456.6d","article-title":"Myeloperoxidase and cardiovascular disease","volume":"2","author":"Hazen","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa035003","article-title":"Prognostic value of myeloperoxidase in patients with chest pain","volume":"34","author":"Hazen","year":"2003","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","article-title":"Plasma myeloperoxidase levels in patients with chronic heart failure","volume":"9","author":"Hazen","year":"2006","journal-title":"Am J Cardiol"},{"key":"25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2005.09.020","article-title":"Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure","volume":"15","author":"Davies","year":"2006","journal-title":"Am Heart J"},{"key":"26","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jacc.2007.02.053","article-title":"Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure","volume":"4","author":"Klein","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"27","first-page":"3060","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase","volume":"26","author":"Doroshow","year":"1986","journal-title":"J Biol Chem"},{"key":"28","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/cvr\/cvz023","article-title":"Cardioprotection in cancer therapy: novel insights with anthracyclines","volume":"11","author":"Asnani","year":"2019","journal-title":"Cardiovasc Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"22","author":"Liu","year":"1984","journal-title":"Science"},{"key":"30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"12","author":"Ardehali","year":"2014","journal-title":"J Clin Invest"},{"key":"31","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"1","author":"Yeh","year":"2012","journal-title":"Nat Med"},{"key":"32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1006\/taap.2002.9532","article-title":"Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy","volume":"18","author":"Wallace","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"key":"33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro","volume":"3","author":"Brunelli","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"34","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"4","author":"Ergin","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia","volume":"1","author":"El-Hawary","year":"2012","journal-title":"J Card Fail"},{"key":"36","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"6","author":"Esteve","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity","volume":"6","author":"Yazdani","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"38","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Gerszten","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"39","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/sj.ejhg.5200702","article-title":"Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms","volume":"9","author":"Visvikis","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Azoulay","year":"2017","journal-title":"Ann Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"2","author":"Picard","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.echo.2008.11.023","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"2","author":"Evangelista","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"43","unstructured":"National Institute of Health. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T14:00:19Z","timestamp":1643119219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,25]]}},"alternative-id":["28182"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28182","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]}}}